Vera Therapeutics Grants Inducement Awards to New Employees Under 2024 Inducement Plan

Vera Therapeutics granted stock options and RSUs to six new employees as part of its Inducement Plan.

Quiver AI Summary

Vera Therapeutics, Inc. announced the grant of inducement awards to six new employees, consisting of non-qualified stock options for 79,050 shares and restricted stock units (RSUs) for 39,915 shares of its Class A common stock, as part of their 2024 Inducement Plan. The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) to assist with attracting new talent. Each stock option has an exercise price of $24.35 and will vest over four years, while the RSUs will also vest over a four-year period starting on November 20, 2025. Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases, with its main product candidate being atacicept, which addresses autoimmune diseases. The company also holds rights to develop other innovative therapies, including VT-109 and MAU868, aimed at addressing B-cell-mediated diseases and kidney transplant complications, respectively.

Potential Positives

Vera Therapeutics has successfully attracted six new employees, incentivized by significant inducement awards, demonstrating the company's growth and ability to recruit talent in a competitive market.
The stock options and restricted stock units (RSUs) granted reflect a commitment to long-term employee engagement and retention, aligning their interests with the company’s performance.
The pricing of the stock options at the closing trading price indicates a favorable market perception of the company's valuation at the time of the grant.
Vera Therapeutics continues to advance its innovative pipeline, including its lead product candidate, atacicept, and the exclusive license agreement for VT-109, highlighting its focus on addressing serious immunological diseases.

Potential Negatives

The issuance of stock options and RSUs for new employees may raise concerns about potential dilution of existing shareholders' equity.
Granting inducement awards could indicate difficulties in attracting talent without such incentives, which might reflect negatively on the company's market reputation.
The extended vesting period of four years may signal challenges in employee retention or job stability within the company.

FAQ

What stock options did Vera Therapeutics grant on November 4, 2025?

Vera Therapeutics granted non-qualified stock options to purchase 79,050 shares of Class A common stock.

How many employees received inducement awards from Vera Therapeutics?

Six new employees received inducement awards under the Vera Therapeutics 2024 Inducement Plan.

What is the exercise price for the stock options awarded?

The exercise price for the stock options is $24.35, equal to the closing price on November 4, 2025.

How will the stock options and RSUs vest for employees?

Both stock options and RSUs will vest over four years, with 25% vesting each year on specified dates.

What therapeutic areas does Vera Therapeutics focus on?

Vera Therapeutics focuses on developing treatments for serious immunological diseases, including lupus nephritis and immunoglobulin A nephropathy.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$VERA Insider Trading Activity

$VERA insiders have traded $VERA stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $VERA stock by insiders over the last 6 months:

PATRICK G ENRIGHT has made 4 purchases buying 250,000 shares for an estimated $5,277,311 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$VERA Hedge Fund Activity

We have seen 104 institutional investors add shares of $VERA stock to their portfolio, and 86 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. added 3,348,117 shares (+inf%) to their portfolio in Q2 2025, for an estimated $78,881,636
HOLOCENE ADVISORS, LP removed 2,199,292 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $51,815,319
MORGAN STANLEY added 1,797,563 shares (+407.9%) to their portfolio in Q2 2025, for an estimated $42,350,584
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,675,367 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $39,471,646
WOODLINE PARTNERS LP added 1,607,523 shares (+160.6%) to their portfolio in Q2 2025, for an estimated $37,873,241
TANG CAPITAL MANAGEMENT LLC added 1,200,000 shares (+800.0%) to their portfolio in Q2 2025, for an estimated $28,272,000
KYNAM CAPITAL MANAGEMENT, LP added 1,026,887 shares (+42.8%) to their portfolio in Q2 2025, for an estimated $24,193,457

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$VERA Analyst Ratings

Wall Street analysts have issued reports on $VERA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 08/07/2025
Scotiabank issued a "Sector Outperform" rating on 06/02/2025
HC Wainwright & Co. issued a "Buy" rating on 06/02/2025

To track analyst ratings and price targets for $VERA, check out Quiver Quantitative's $VERA forecast page.

$VERA Price Targets

Multiple analysts have issued price targets for $VERA recently. We have seen 4 analysts offer price targets for $VERA in the last 6 months, with a median target of $54.0.

Here are some recent targets:

Dina Ramadane from B of A Securities set a target price of $48.0 on 10/16/2025
Anupam Rama from JP Morgan set a target price of $53.0 on 08/07/2025
Greg Harrison from Scotiabank set a target price of $55.0 on 06/02/2025
Arthur He from HC Wainwright & Co. set a target price of $85.0 on 06/02/2025

Full Release

BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on November 4, 2025 has an exercise price per share equal to $24.35, Vera Therapeutics’ closing trading price on November 4, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of November 20, 2025, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com .

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
[email protected]

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
[email protected]